Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Highfield Biopharmaceuticals Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals sector. This matter is being handled by 1 distinct examiner, MITCHELL, EDWIN COLEMAN, who is the busiest examiner for the company with 1 pending action. The entire active portfolio is localized within 1 distinct art unit. This indicates a focused prosecution effort where a single examiner oversees the current workload.
The presence of 1 pending office action suggests that the company's current activity in Biotechnology & Pharmaceuticals is focused on a single matter. MITCHELL, EDWIN COLEMAN is the sole examiner responsible for this 1 pending office action, making his review critical to the portfolio. Because the work is confined to 1 distinct art unit, the technical subject matter is likely specialized. Practitioners should focus on the specific requirements of that 1 distinct art unit when addressing the 1 pending office action assigned to MITCHELL, EDWIN COLEMAN.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MITCHELL, EDWIN COLEMAN | 1 | 32.1% | +65.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563311 | APPLICATION OF PHARMACEUTICAL COMPOSITION HAVING SPECIFIC DRUG-TO-LIPID RATIO IN ANTITUMOR | MITCHELL, EDWIN COLEMAN | 12d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563311 | APPLICATION OF PHARMACEUTICAL COMPOSITION HAVING SPECIFIC DRUG-TO-LIPID RATIO IN ANTITUMOR | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Final Rejection | 12d | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHighfield Biopharmaceuticals Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Edwin Coleman Mitchell has the most, with 1 of Highfield Biopharmaceuticals Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
